Abstract: Disclosed are a mount control system and method for vehicles in which a camera of an electronically controlled suspension system with road preview photographs a road surface condition of a road ahead of a vehicle, a suspension controller determines a road surface state of the road based on photographed information of the camera, and a mount controller controls semi-active mounts to be in an on state or in an off state based on road surface state determination information transmitted from the suspension controller and values detected by wheel acceleration sensors mounted on wheels of the vehicle, so as to improve not only NVH performance but also driving vibration damping performance depending on the road surface state.

Abstract: Provided is a display device including a display panel, an optical sensor, a timing controller, a scan driver, a data driver, and an image controller. The timing controller controls an image refresh rate of the display panel based on are fresh rate control signal. Thus, the display device provides improved visibility.

Abstract: The present disclosure relates to a stripping device and a stripping method, and more particularly, to a stripping device including: a distillation column of which at least a part or the entirety of a lower portion is perforated; a stripping vessel integrally connected to the lower portion of the distillation column; and one or more spray nozzles provided at an upper portion of the stripping vessel, and a stripping method using the same.

Abstract: The present invention relates to an ophthalmic composition containing recoflavone for the treatment of dry eye disease. Specifically, in order to maximize the improvement of symptoms of dry eye, the present invention relates to an ophthalmic composition containing a certain concentration of the active ingredient and at least one of polyoxyethylene castor oil derivatives or poloxamers which are permeation enhancers, so that the active ingredient, recoflavone, can sufficiently penetrate the cornea in vivo to exhibit significant therapeutic effects.

Abstract: The present invention relates to an ophthalmic composition containing recoflavone for the treatment of dry eye disease. Specifically, in order to maximize the improvement of symptoms of dry eye, the present invention relates to an ophthalmic composition containing a certain concentration of the active ingredient and at least one of polyoxyethylene castor oil derivatives or poloxamers which are permeation enhancers, so that the active ingredient, recoflavone, can sufficiently penetrate the cornea in vivo to exhibit significant therapeutic effects.

Abstract: A polarizing plate and an optical display apparatus are disclosed. A polarizing plate includes a polarizer and a protective layer on at least one surface of the polarizer, and the polarizer includes a polyvinyl alcohol film containing a dichroic substance and contains zinc cations and potassium cations, and the polarizing plate has a value of 0.1 or less, as calculated according to Equation 1.

Abstract: A cathode active material for a lithium secondary battery includes a lithium-transition metal oxide including nickel (Ni), cobalt (Co), manganese (Mn), strontium (Sr) and sulfur (S). A mole fraction of nickel based on the total number of moles of nickel, cobalt and manganese in the lithium-transition metal oxide is 0.9 or more. A molar ratio of cobalt relative to manganese in the lithium-transition metal oxide is in a range from 0.9 to 1.5. A molar ratio of strontium (Sr) relative to sulfur (S) in the lithium-transition metal oxide is greater than 0, and 4 or less.

Abstract: The present invention relates to: a substituted thiazolidinedione derivative compound having a novel structure acting as a sterol regulatory element-binding protein-1 (SREBP1) inhibitor, a hydrate thereof, or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition for preventing or treating cancer, comprising same as an active ingredient.

Abstract: The present invention relates to an ethylene/alpha-olefin copolymer having a high weight average molecular weight and narrow molecular weight distribution, and at the same time, a reduced characteristic relaxation time, thereby showing excellent physical properties, and a method for preparing the same. A resin composition having improved volume resistance and excellent light transmittance may be prepared by using such ethylene/alpha-olefin copolymer. Accordingly, the ethylene/alpha-olefin copolymer may be utilized in various uses in electrical and electronic industrial fields.

Abstract: Proposed is a blood-brain barrier penetrating drug delivery system in which sialyllactose, which can penetrate the blood-brain barrier, is linked to a drug. The drug delivery system can deliver low-molecular weight small molecule drugs and high-molecular weight antibodies to the brain, and thus can be applied to various types of brain disease therapeutic agents or diagnostic substances.

Abstract: A recycling method of a waste lithium ion secondary battery may include (a) charging a waste lithium ion secondary battery into a pyrolysis furnace, (b) increasing the internal temperature of the pyrolysis furnace to induce self-heating of the waste lithium ion secondary battery, (c) maintaining a self-heating reaction of the waste lithium ion secondary battery, (d) discharging a first powder formed after completing the self-heating reaction of the waste lithium ion secondary battery, and (e) injecting the first powder into water, dissolving a lithium component included in the first powder, and separating and recovering a lithium aqueous solution, a precipitate settled in the lithium aqueous solution, and a floating material on the surface of the lithium aqueous solution, separately.

Abstract: In a method for ameliorating or treating a respiratory disease, a composition including a Lysimachia mauritiana extract as effective component is administered to a subject in need thereof. Since the Lysimachia mauritiana extract is effective in reducing the production amount of the chemokine RANTES, an inflammatory mediator, from bronchial epithelial cells, which are respiratory cells, the composition can be advantageously used as a functional health food or medicine for respiratory diseases including asthma or chronic obstructive pulmonary disease (COPD).

Abstract: The present invention relates to a multi-stage decellularized mammal-derived tissue supplement, prepared by a method comprising: a preparation step for preparing tissue of a non-human mammal; a pretreatment step for pretreating the tissue; a first inactivation step for inactivating a virus included in the pretreated tissue using alcohol; a primary decellularization step for removing cells from the virus-inactivated tissue using an aqueous basic solution; a secondary decellularization step for removing cells by enzymatically treating the primary decellularized tissue; and a second inactivation step for inactivating a virus included in the decellularized tissue using an acid, and wherein the DNA content in the tissue subjected to the pretreatment step to the second inactivation step is 50 ng/mg or less, and the degradation time using 100 U/ml of collagenase is at least 90 hours; and a method for preparing the same.

Abstract: The present invention relates to a multi-stage decellularized mammal-derived tissue matrix, prepared by a method comprising: a preparation step for preparing tissue of a non-human mammal; a pretreatment step for pretreating the tissue; a first inactivation step for inactivating a virus included in the pretreated tissue using alcohol; a primary decellularization step for removing cells from the virus-inactivated tissue using an aqueous basic solution; a secondary decellularization step for removing cells by enzymatically treating the primary decellularized tissue; and a second inactivation step for inactivating a virus included in the decellularized tissue using an acid, and wherein the DNA content in the tissue subjected to the second inactivation step is 50 ng/mg or less, and the reduction rate (L) of the elastin content in the tissue subjected to the pretreatment step to the second inactivation step is 20% or less; and a method for preparing the same.

Abstract: The present disclosure relates to an isolated anti-FcRN antibody, which is an antibody binding to FcRN (stands for neonatal Fc receptor, also called FcRP, FcRB or Brambell receptor) that is a receptor with a high affinity for IgG or a fragment thereof, a method of preparing thereof, a composition for treating autoimmune disease, which comprises the antibody, and a method of treating and diagnosing autoimmunre diseases using the antibody. The FcRn-specific antibody according to the present disclosure binds to FcRn non-competitively with IgG to reduce serum pathogenic auto-antibody levels, and thus can be used for the treatment of autoimmune diseases.

Abstract: A method of fabricating a semiconductor device includes providing a substrate, forming a target film, a first mask film, a second mask film, and an upper mask pattern on the substrate, forming a first spacer pattern that includes a first line portion and a second line portion, and a folding portion that connects the first line portion and the second line portion, forming a slit mask pattern that partially covers the first spacer pattern, forming a first mask pattern by patterning the second mask film using the slit mask pattern and the first spacer pattern as an etching mask, forming a second spacer pattern, forming a second mask pattern by patterning the first mask film using the second spacer pattern as an etching mask, and forming a plurality of target patterns by patterning the target film using the second mask pattern as an etching mask.

Abstract: A multilayer ceramic electronic component includes a body including a dielectric layer and an internal electrode, and an external electrode disposed on the exterior of the body. The dielectric layer includes a plurality of dielectric grains and a grain boundary present between the dielectric grains. A molar ratio (Al/Ti) of Al and Ti included in the grain boundary satisfies 0.022 to 0.028.

Abstract: A reduced metal powder prepared by processing a waste lithium ion secondary battery to recover valuable metals from the waste lithium ion secondary battery in an economical and environmentally friendly manner is described. To achieve the goal described above, the reduced metal powder according to an embodiment is prepared by pyrolyzing a waste lithium ion secondary battery, and contains metals Ni and Co and has magnetism.

Abstract: There is provided a novel compound of Formula I and a use thereof for the prevention or treatment of a disease associated with SOS1. In one aspect of the present invention, the novel compound is useful for the prevention or treatment of a SOS1 mediated disease such as cancer and RASopathy by inhibiting the interaction between SOS1 and RAS family proteins or between SOS1 and RAC1.

Abstract: Disclosed is an organic light-emitting display device, which prevents lateral current leakage by providing a structure on a bank so as to cut off an organic material, which is formed in a subsequent process, around the structure.